Business of Cannabis
2025 remains unclear. The transitional period between experimentation and generalisation could be extended to 2025, still without cannabis flowers and with a major unknown both in terms of funding and the possibility of including new patients.
The patients we contacted who were included in the trial, and who already felt sidelined by the absence of cannabis flowers in the generalised system, told us that their only solution would be to go back either to growing their own cannabis or to the black market to obtain supplies, with the risk of coming across flowers containing bacteria harmful to their immune systems, which have been damaged by their various illnesses.
There are currently two manufacturers ready for 2025 in France, which will also have to wait and finance the year 2025 out of their own pockets, with no possibility of producing oils outside the R&D framework or exporting their flower production for the time being, to Germany for example.
Read full article
https://businessofcannabis.com/frances-medical-cannabis-launch-likely-to-be-delayed-until-2026/
